Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (224)
Related Products (224)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
ErbB-2-binding peptide-2
0 ImagesCat. No.: HY-P12120CAS No.: 499773-67-0Synonyms: KCCYSLErbB-2-binding peptide-2 (KCCYSL) is a peptide targeting ErbB-2/HER2, which specifically binds to the extracellular domain of HER2 and accumulates in HER2-expressing cancer cells. When radiolabeled, ErbB-2-binding peptide-2 serves as a SPECT/CT and PET imaging agent, enabling the visualization of HER2-expressing tumor xenografts. ErbB-2-binding peptide-2 is applicable to research related to ovarian cancer and breast cancer.
-
DOTA Zoledronate
0 ImagesCat. No.: HY-139564CAS No.: 1908409-18-6DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases.
-
cFLFLF
0 ImagesCat. No.: HY-P11718CAS No.: 1000977-62-7cFLFLF is a FPR-specific peptide. cFLFLF is sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a DOTA through a lysine (K) spacer and finally labeled with 64Cu-CuCl2 to form cFLFLFKPEG-64Cu. cFLFLFKPEG-64Cu is a neutrophil-specific PET imaging agent.
-
Maleimide-NOTA TFA
0 ImagesCat. No.: HY-W087027AMaleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.
-
NCS-MP-NODA
0 ImagesCat. No.: HY-164576CAS No.: 1374994-81-6Synonyms: NODA-Bz-SCNNCS-MP-NODA (NODA-Bz-SCN) is a NODA-derived bifunctional chelator. NCS-MP-NODA can conjugate with biomolecules including the RGD tripeptide, and is used for aluminum-[18F] fluoride-based positron emission tomography (PET) radiolabeling. NCS-MP-NODA can conjugate with the free lysine amino group of the PD-L1-specific peptide DK221 to generate DK222, which can be radiolabeled with 18F to form [18F]DK222. NCS-MP-NODA can be used in studies related to triple-negative breast cancer, melanoma and colon cancer.
-
cRY9M acetate
0 ImagesCat. No.: HY-P11853AcRY9M acetate is a cyclic peptide that binds to FGFR1, with a KD value of 58 nM. cRY9M acetate binds specifically to FGFR1, exhibits enhanced in vivo stability, and shows extremely low degradation in blood, urine and liver homogenate after injection. cRY9M acetate displays significant specific uptake in FGFR1-positive tumor xenograft models, while its uptake decreases in FGFR1-negative tumor models and blocking models. The NOTA-chelated precursor of cRY9M acetate can be labeled with 68Ga to obtain [68Ga]Ga-NOTA-cRY9M, which is used for research on non-invasive imaging of FGFR1 expression in non-small cell lung cancer.
-
BCN-NODAGA
0 ImagesCat. No.: HY-164590CAS No.: 2256055-98-6BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
Pendetide
0 ImagesCat. No.: HY-P10012CAS No.: 148805-91-8Synonyms: GYK-DTPAPendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma. Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
DOTA-SMIC-1014
0 ImagesCat. No.: HY-P11864DOTA-SMIC-1014 is a DOTA chelator-conjugated precursor of the c-Met-targeting peptide SMIC-1014 (HY-P11863). DOTA-SMIC-1014 binds to the extracellular domain of c-Met (Kd = 42.83 nM). After radiolabeling to [68Ga]Ga-SMIC-1014, DOTA-SMIC-1014 acts as a positron emission tomography (PET) probe that achieves specific tumor uptake in xenografts and functions as a diagnostic probe targeting c-Met. SMIC-1014 can be used in research related to colon cancer, hepatocellular carcinoma, and prostate cancer.
-
NOTA-PTP
0 ImagesCat. No.: HY-P11849NOTA-PTP is an aggregation agent and imaging agent targeting Plectin-1. NOTA-PTP achieves targeted accumulation in Plectin-1-expressing cells and tumors. NOTA-PTP accumulates in a time-dependent manner in pancreatic ductal adenocarcinoma cells. NOTA-PTP serves as a precursor for the synthesis of [68Ga]Ga-NOTA-PTP, a Plectin-1-targeted positron emission tomography radiotracer for pancreatic ductal adenocarcinoma imaging. NOTA-PTP can be used in studies related to pancreatic ductal adenocarcinoma.
-
TA-DOTA
0 ImagesCat. No.: HY-164599CAS No.: 2451069-30-8TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
ProX1-(SS)-DOTAGA
0 ImagesCat. No.: HY-185120ACAS No.: 3084147-67-8ProX1-(SS)-DOTAGA (Compound 12b) is the unbound portion of the radionuclide in the compound and can be used for targeted delivery to diseases characterized by ACP3 expression.
-
Tabituximab barzuxetan (exclude Y90)
0 ImagesCat. No.: HY-P99581CAS No.: 1612758-88-9Synonyms: OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma.
-
OI-3
0 ImagesCat. No.: HY-P992430OI-3 is a monoclonal antibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with 212Pb to form 212Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma.
-
cTMTP1
0 ImagesCat. No.: HY-P11814Synonyms: Cyclic TMTP1cTMTP1 (Cyclic TMTP1) is the cyclic form of TMTP1 (HY-P11815). TMTP1 is a tumor-targeting peptide that selectively targets highly metastatic tumor cells. The cTMTP1-based [68Ga]Ga-DOTA-cTMTP1 probe is used for visualization of hepatocellular carcinoma. cTMTP1 can form a 68Ga-DOTA radiotracer that accumulates in highly metastatic cervical cancer cells and is used for microPET tumor visualization. cTMTP1 is applicable to research related to hepatocellular carcinoma and cervical cancer.
-
NH2-NODAGA hydrochloride
0 ImagesCat. No.: HY-164575BNH2-NODAGA hydrochloride is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., 68Ga, 177Lu). NH2-NODAGA hydrochloride can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research.
-
DOTAEt
0 ImagesCat. No.: HY-164653CAS No.: 137076-50-7DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
Hynic-toc
0 ImagesCat. No.: HY-P10232CAS No.: 257943-19-4Synonyms: HYNIC-Tyr3-octreotideHynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging. Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
